Logo

DnaNudge Inks Distribution Deal for SARS-CoV-2 Test, Other Products in Spain

Sep 07, 2021 | staff reporter

NEW YORK — UK diagnostics firm DnaNudge said on Tuesday that it has signed an exclusive distribution agreement for its PCR-based SARS-CoV-2 test and other genetic testing products in Spain with Quirónprevención.

Under the terms of the deal, Madrid-based Quirónprevención will offer DnaNudge's CovidNudge, a CE-IVD-marked point-of-care assay for SARS-CoV-2. Quirónprevención — a part of Spanish hospital group Quirónsalud — will also distribute DnaNudge's nutrition service, which uses an individual's genetic profile to make eating recommendations, and its upcoming skincare service.

Financial and other terms of the agreement were not disclosed.

Last month, DnaNudge raised $60 million in private financing.

Filed under

Molecular Diagnostics
Point-of-Care Testing
Infectious Disease
COVID-19
Business News
distribution agreement
Europe
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.